Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Pediatrix Medical (MD) over the last 10 years, with Q3 2025 value amounting to $183.3 million.

  • Pediatrix Medical's Accumulated Expenses changed N/A to $183.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.3 million, marking a year-over-year change of. This contributed to the annual value of $215.4 million for FY2024, which is 1151.92% up from last year.
  • Pediatrix Medical's Accumulated Expenses amounted to $183.3 million in Q3 2025.
  • In the past 5 years, Pediatrix Medical's Accumulated Expenses registered a high of $215.4 million during Q4 2024, and its lowest value of $74.1 million during Q1 2025.
  • Its 4-year average for Accumulated Expenses is $158.0 million, with a median of $166.7 million in 2023.
  • In the last 5 years, Pediatrix Medical's Accumulated Expenses crashed by 238.54% in 2023 and then soared by 1151.92% in 2024.
  • Quarter analysis of 4 years shows Pediatrix Medical's Accumulated Expenses stood at $197.8 million in 2022, then decreased by 2.39% to $193.1 million in 2023, then grew by 11.52% to $215.4 million in 2024, then fell by 14.88% to $183.3 million in 2025.
  • Its Accumulated Expenses was $183.3 million in Q3 2025, compared to $133.6 million in Q2 2025 and $74.1 million in Q1 2025.